ATAI Life Sciences NV
NASDAQ:ATAI
Intrinsic Value
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. [ Read More ]
The intrinsic value of one ATAI stock under the Base Case scenario is 2.4 USD. Compared to the current market price of 1.93 USD, ATAI Life Sciences NV is Undervalued by 20%.
Valuation Backtest
ATAI Life Sciences NV
Run backtest to discover the historical profit from buying and selling ATAI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ATAI Life Sciences NV
Current Assets | 185.6m |
Cash & Short-Term Investments | 179.3m |
Receivables | 4.1m |
Other Current Assets | 2.3m |
Non-Current Assets | 107.9m |
Long-Term Investments | 91.7m |
PP&E | 2.2m |
Other Non-Current Assets | 14m |
Current Liabilities | 20.1m |
Accounts Payable | 4.6m |
Accrued Liabilities | 14.8m |
Other Current Liabilities | 715k |
Non-Current Liabilities | 30.4m |
Long-Term Debt | 17.9m |
Other Non-Current Liabilities | 12.5m |
Earnings Waterfall
ATAI Life Sciences NV
Revenue
|
314k
USD
|
Operating Expenses
|
-125.8m
USD
|
Operating Income
|
-125.5m
USD
|
Other Expenses
|
85.2m
USD
|
Net Income
|
-40.2m
USD
|
Free Cash Flow Analysis
ATAI Life Sciences NV
ATAI Profitability Score
Profitability Due Diligence
ATAI Life Sciences NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
ATAI Life Sciences NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ATAI Solvency Score
Solvency Due Diligence
ATAI Life Sciences NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
ATAI Life Sciences NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATAI Price Targets Summary
ATAI Life Sciences NV
According to Wall Street analysts, the average 1-year price target for ATAI is 10.9 USD with a low forecast of 5.15 USD and a high forecast of 22.05 USD.
Ownership
ATAI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ATAI Price
ATAI Life Sciences NV
Average Annual Return | -63.01% |
Standard Deviation of Annual Returns | 3.38% |
Max Drawdown | -95% |
Market Capitalization | 320.4m USD |
Shares Outstanding | 166 010 000 |
Percentage of Shares Shorted | 4.62% |
ATAI News
Last Important Events
ATAI Life Sciences NV
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
ATAI Life Sciences NV
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one ATAI stock under the Base Case scenario is 2.4 USD.
Compared to the current market price of 1.93 USD, ATAI Life Sciences NV is Undervalued by 20%.